BTKi FAQ
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Released: March 31, 2022

Expiration: March 30, 2023

Activity

Progress
1
Course Completed

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:

  • For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
  • What is the optimal therapy for a patient with del(17p) CLL?
  • When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
  • What are best practices in the use of BTK inhibitors for patients with MCL?
  • How can BTK inhibitor resistance occur?
  • How might investigational noncovalent BTK inhibitors be used should they be approved?

What are key adverse events with BTK inhibitors?